Physicochemical and functional assessment of messenger RNA 5′Cap-end impurities under forced degradation conditions
The 5'Cap is a modified nucleotide structure added to the 5'end of mRNA, which plays a critical role in stability and translation of the molecule. Accurate characterization of 5'Cap impurities is crucial during development of mRNA therapeutics. Here, we utilized orthogonal liquid chromatography-mass spectrometry (LC-MS) workflows to characterize Cap-1-modified mRNA. A complex mixture of uncapped and, notably, 5'Cap chemical degradation variants, was detected. We subjected Cap-1 analogs to process-related forced degradation conditions and characterized multiple degradation routes of the 5'Cap structure, including hydrolysis and depurination. 5'Cap hydrolysis was observed in a representative <i>in vitro</i> transcription (IVT) reaction buffer and was driven by factors including pH, temperature, and the presence of spermidine and MgCl<sub>2</sub>. Method-induced artifactual degradation occurred during LC-MS data acquisition, emphasizing the importance of using reference standards and optimizing methods to reduce such artifacts. We investigated the effect of 5'Cap degradation on expression and reactogenicity <i>in vitro</i> using model mRNAs with elevated impurity levels. mRNA 5'Cap degradation impurities significantly impacted protein expression but did not trigger innate immune response pathways. 5'Cap degradation impurities should be considered as a critical quality attribute of mRNA therapeutics and should be monitored during production, purification, formulation, and storage.
Authors
- Tracy Nissan (ORCID: https://orcid.org/0000-0003-0482-0543)
- Ruma Rani (ORCID: https://orcid.org/0000-0003-4858-0449)
- Stefano Leone (ORCID: https://orcid.org/0000-0001-6339-6397)
- Eivor Örnskov (ORCID: https://orcid.org/0000-0002-0672-4531)
- J A Button
- Stephanie M. Bates (ORCID: https://orcid.org/0000-0003-2708-6118)
- Diamantis C. Sideris (ORCID: https://orcid.org/0000-0001-6518-0098)
- Sara Maria David Trabulo (ORCID: https://orcid.org/0000-0002-3178-2119)
- Fritz Schweikart (ORCID: https://orcid.org/0000-0002-2201-7896)
- Nicholas J. Bond (ORCID: https://orcid.org/0000-0002-0312-7360)
- George Thom (ORCID: https://orcid.org/0000-0002-1029-3551)
- Aditya Murthy (ORCID: https://orcid.org/0000-0002-6130-9568)
- James C. Hutchinson
- Chandra Shekhar Lal (ORCID: https://orcid.org/0000-0002-6887-8376)
- R. D. Shannon
Institutions
- AstraZeneca (South Korea) (KR)
- AstraZeneca (Australia) (AU)
- AstraZeneca (Italy) (IT)
- AstraZeneca (Spain) (ES)
Publication Details
- Journal
- Molecular Therapy — Nucleic Acids
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1016/j.omtn.2025.102570
- Citations
- 2
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- AstraZeneca